MAPT and dementia: Studies have demonstrated that the accuracy of plasma NfLs in distinguishing AD dementia from healthy controls is close to the accuracy of established CSF AD biomarkers (total tau, phosphorylated tau, and β-amyloid (Aβ)) and higher than the accuracy of plasma tau [9].